BACKGROUND: Few study has been done to evaluate the stability and superiority of normalizers for serum microRNA (miRNA) study in cardiovascular disease. Therefore, the aim of this study is to assess the suitability of several common normalizers (miR-16, SNOU6, 5S, miR-19b, miR-24, miR-15b, let 7i) in cardiovascular disease. METHODS: We evaluated the stability of the seven circulating miRNAs as reference genes in the blood samples from patients with cardiovascular disease [heart failure (HF) and hypertension] and healthy people. Stability was quantified by combining BestKeeper, NormFinder and comparative delta Cq analysis. RESULTS: A total of 62 subjects were included in this study, of which 25 patients were with HF, 10 patients were with hypertension, and 27 were healthy people. The analysis from both BestKeeper and comparative delta ct analysis demonstrated that let-7i and miR-16 showed the best performance [the standard deviations (SD) in BestKeeper for let-7i and miR-16 were 0.60 and 0.72, and the mean SD in comparative delta ct analysis for let-7i and miR-16 were 1.79 and 1.82, respectively], while SNOU6 and 5S had the highest variability. In NormFinder analysis, miR-15 show best stability (ρ=0.029), followed by miR-19b (ρ=0.037), let-7i (ρ=0.064), SNOU6 (ρ=0.064), 5S (ρ=0.064), miR-16 (ρ=0.064), while miR-24 (ρ=0.075) showed worst stability. CONCLUSIONS: This study pointed out that in the serum studies focused on cardiovascular disease, let-7i and miR-16 had the best performance, while SNOU6 and 5S were not suitable as reference gene. This study indicate that the selection of an optimal reference genes is important to get an accurate result in serum miRNA studies, the findings are of clinical significance to guide the further miRNA studies or tests.
BACKGROUND: Few study has been done to evaluate the stability and superiority of normalizers for serum microRNA (miRNA) study in cardiovascular disease. Therefore, the aim of this study is to assess the suitability of several common normalizers (miR-16, SNOU6, 5S, miR-19b, miR-24, miR-15b, let 7i) in cardiovascular disease. METHODS: We evaluated the stability of the seven circulating miRNAs as reference genes in the blood samples from patients with cardiovascular disease [heart failure (HF) and hypertension] and healthy people. Stability was quantified by combining BestKeeper, NormFinder and comparative delta Cq analysis. RESULTS: A total of 62 subjects were included in this study, of which 25 patients were with HF, 10 patients were with hypertension, and 27 were healthy people. The analysis from both BestKeeper and comparative delta ct analysis demonstrated that let-7i and miR-16 showed the best performance [the standard deviations (SD) in BestKeeper for let-7i and miR-16 were 0.60 and 0.72, and the mean SD in comparative delta ct analysis for let-7i and miR-16 were 1.79 and 1.82, respectively], while SNOU6 and 5S had the highest variability. In NormFinder analysis, miR-15 show best stability (ρ=0.029), followed by miR-19b (ρ=0.037), let-7i (ρ=0.064), SNOU6 (ρ=0.064), 5S (ρ=0.064), miR-16 (ρ=0.064), while miR-24 (ρ=0.075) showed worst stability. CONCLUSIONS: This study pointed out that in the serum studies focused on cardiovascular disease, let-7i and miR-16 had the best performance, while SNOU6 and 5S were not suitable as reference gene. This study indicate that the selection of an optimal reference genes is important to get an accurate result in serum miRNA studies, the findings are of clinical significance to guide the further miRNA studies or tests.
Authors: Fabian Benz; Christoph Roderburg; David Vargas Cardenas; Mihael Vucur; Jérémie Gautheron; Alexander Koch; Henning Zimmermann; Jörn Janssen; Lukas Nieuwenhuijsen; Mark Luedde; Norbert Frey; Frank Tacke; Christian Trautwein; Tom Luedde Journal: Exp Mol Med Date: 2013-09-20 Impact factor: 8.718
Authors: Christine Wahlquist; Dongtak Jeong; Agustin Rojas-Muñoz; Changwon Kho; Ahyoung Lee; Shinichi Mitsuyama; Alain van Mil; Woo Jin Park; Joost P G Sluijter; Pieter A F Doevendans; Roger J Hajjar; Mark Mercola Journal: Nature Date: 2014-03-12 Impact factor: 49.962
Authors: María N Lardizábal; Ana L Nocito; Stella M Daniele; Leonardo A Ornella; Javier F Palatnik; Luis M Veggi Journal: PLoS One Date: 2012-05-01 Impact factor: 3.240
Authors: Demetris Koutalianos; Andrie Koutsoulidou; Chrystalla Mytidou; Andrea C Kakouri; Anastasis Oulas; Marios Tomazou; Tassos C Kyriakides; Marianna Prokopi; Konstantinos Kapnisis; Nikoletta Nikolenko; Chris Turner; Anna Lusakowska; Katarzyna Janiszewska; George K Papadimas; Constantinos Papadopoulos; Evangelia Kararizou; George M Spyrou; Geneviève Gourdon; Eleni Zamba Papanicolaou; Grainne Gorman; Andreas Anayiotos; Hanns Lochmüller; Leonidas A Phylactou Journal: Mol Ther Methods Clin Dev Date: 2021-09-14 Impact factor: 6.698
Authors: Sharmilee Vetrivel; Ru Zhang; Mareen Engel; Barbara Altieri; Leah Braun; Andrea Osswald; Martin Bidlingmaier; Martin Fassnacht; Felix Beuschlein; Martin Reincke; Alon Chen; Silviu Sbiera; Anna Riester Journal: Front Endocrinol (Lausanne) Date: 2021-02-22 Impact factor: 5.555